The global PEGylated drugs market is expected to grow at a CAGR of 7.2% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of chronic diseases and rising demand for biologics in emerging economies.
The global PEGylated drugs market by type is segmented into linkers and croslinkers. The linker segment accounted for the largest share in 2018, followed by croslinkers. The linker segment is expected to maintain its dominance throughout the forecast period owing to its wide range of applications across various therapeutic areas such as cancer, chronic kidney diseases, hepatitis, multiple sclerosis (MS), hemophilia and gastrointestinal disorders (GID).
The global PEGylated drugs market by application includes cancer, chronic kidney diseases (CKD), hepatitis B virus infection (HBV), hepatitis C virus infection (HCV) and multiple sclerosis (MS). Cancer accounted for the largest share in 2018 due to high incidence rates globally coupled with an increase in awareness about cancer prevention measures among people worldwide. Chronic kidney disease was ranked second owing to high prevalence rates globally coupled with an increase in awareness about CKD prevention measures among people worldwide. Hepatitis B virus infection was ranked third due to high incidence rates globally coupled with an increase in awareness about HBV prevention measures among people worldwide while hepatitis C virus infection was ranked fourth due to low incidence rates globally coupled with a decrease in awareness about HCV prevention measures among people worldwide.
Some Of The Growth Factors Of This Market:
- The market for PEGylated drugs is expected to reach $4,814 million by 2025.
- The growth of the market for PEGylated drugs is driven by the increasing prevalence of chronic diseases and rising demand for cost-effective treatments.
- Increasing number of new product launches in the pipeline.
- Increasing number of mergers and acquisitions.
Industry Growth Insights published a new data on “PEGylated Drugs Market”. The research report is titled “PEGylated Drugs Market research by Types (Linkers, Cross-Linkers, Other), By Applications (Cancer, Chronic Kidney Diseases, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorders), By Players/Companies Thermo Fisher Scientific, Merck, Johnson & Johnson, Creative PEGworks, NOF, Quanta BioDesign Celares Biomatrik, Iris Biotech Laysan Bio, ...”.
Scope Of The Report
Report Attributes
Report Details
Report Title
PEGylated Drugs Market Research Report
By Type
Linkers, Cross-Linkers, Other
By Application
Cancer, Chronic Kidney Diseases, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorders
By Companies
Thermo Fisher Scientific, Merck, Johnson & Johnson, Creative PEGworks, NOF, Quanta BioDesign Celares Biomatrik, Iris Biotech Laysan Bio, ...
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global PEGylated Drugs Market Report Segments:
The global PEGylated Drugs market is segmented on the basis of:
Types
Linkers, Cross-Linkers, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Chronic Kidney Diseases, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorders
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Thermo Fisher Scientific
- Merck
- Johnson & Johnson
- Creative PEGworks
- NOF
- Quanta BioDesign Celares Biomatrik
- Iris Biotech Laysan Bio
- ...
Highlights of The PEGylated Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Linkers
- Cross-Linkers
- Other
- By Application:
- Cancer
- Chronic Kidney Diseases
- Hepatitis
- Multiple Sclerosis
- Hemophilia
- Gastrointestinal Disorders
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the PEGylated Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
PEGylated drugs are medications that have been chemically modified with a polyethylene glycol molecule. PEG is a long chain molecule that is similar to, but much more water-soluble than, human blood plasma. This makes it possible to increase the drug's absorption and decrease its potential for interactions with other medications or substances in the body.
Some of the key players operating in the pegylated drugs market are Thermo Fisher Scientific, Merck, Johnson & Johnson, Creative PEGworks, NOF, Quanta BioDesign Celares Biomatrik, Iris Biotech Laysan Bio.
The pegylated drugs market is expected to grow at a compound annual growth rate of 7.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. PEGylated Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. PEGylated Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. PEGylated Drugs Market - Supply Chain
4.5. Global PEGylated Drugs Market Forecast
4.5.1. PEGylated Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. PEGylated Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. PEGylated Drugs Market Absolute $ Opportunity
5. Global PEGylated Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. PEGylated Drugs Market Size and Volume Forecast by Type
5.3.1. Linkers
5.3.2. Cross-Linkers
5.3.3. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global PEGylated Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. PEGylated Drugs Market Size and Volume Forecast by Application
6.3.1. Cancer
6.3.2. Chronic Kidney Diseases
6.3.3. Hepatitis
6.3.4. Multiple Sclerosis
6.3.5. Hemophilia
6.3.6. Gastrointestinal Disorders
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global PEGylated Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. PEGylated Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global PEGylated Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. PEGylated Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global PEGylated Drugs Demand Share Forecast, 2019-2029
9. North America PEGylated Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America PEGylated Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America PEGylated Drugs Market Size and Volume Forecast by Application
9.4.1. Cancer
9.4.2. Chronic Kidney Diseases
9.4.3. Hepatitis
9.4.4. Multiple Sclerosis
9.4.5. Hemophilia
9.4.6. Gastrointestinal Disorders
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America PEGylated Drugs Market Size and Volume Forecast by Type
9.7.1. Linkers
9.7.2. Cross-Linkers
9.7.3. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America PEGylated Drugs Demand Share Forecast, 2019-2029
10. Latin America PEGylated Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America PEGylated Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America PEGylated Drugs Market Size and Volume Forecast by Application
10.4.1. Cancer
10.4.2. Chronic Kidney Diseases
10.4.3. Hepatitis
10.4.4. Multiple Sclerosis
10.4.5. Hemophilia
10.4.6. Gastrointestinal Disorders
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America PEGylated Drugs Market Size and Volume Forecast by Type
10.7.1. Linkers
10.7.2. Cross-Linkers
10.7.3. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America PEGylated Drugs Demand Share Forecast, 2019-2029
11. Europe PEGylated Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe PEGylated Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe PEGylated Drugs Market Size and Volume Forecast by Application
11.4.1. Cancer
11.4.2. Chronic Kidney Diseases
11.4.3. Hepatitis
11.4.4. Multiple Sclerosis
11.4.5. Hemophilia
11.4.6. Gastrointestinal Disorders
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe PEGylated Drugs Market Size and Volume Forecast by Type
11.7.1. Linkers
11.7.2. Cross-Linkers
11.7.3. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe PEGylated Drugs Demand Share, 2019-2029
12. Asia Pacific PEGylated Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific PEGylated Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific PEGylated Drugs Market Size and Volume Forecast by Application
12.4.1. Cancer
12.4.2. Chronic Kidney Diseases
12.4.3. Hepatitis
12.4.4. Multiple Sclerosis
12.4.5. Hemophilia
12.4.6. Gastrointestinal Disorders
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific PEGylated Drugs Market Size and Volume Forecast by Type
12.7.1. Linkers
12.7.2. Cross-Linkers
12.7.3. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific PEGylated Drugs Demand Share, 2019-2029
13. Middle East & Africa PEGylated Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa PEGylated Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa PEGylated Drugs Market Size and Volume Forecast by Application
13.4.1. Cancer
13.4.2. Chronic Kidney Diseases
13.4.3. Hepatitis
13.4.4. Multiple Sclerosis
13.4.5. Hemophilia
13.4.6. Gastrointestinal Disorders
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa PEGylated Drugs Market Size and Volume Forecast by Type
13.7.1. Linkers
13.7.2. Cross-Linkers
13.7.3. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa PEGylated Drugs Demand Share, 2019-2029
14. Competition Landscape
14.1. Global PEGylated Drugs Market: Market Share Analysis
14.2. PEGylated Drugs Distributors and Customers
14.3. PEGylated Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Thermo Fisher Scientific
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Johnson & Johnson
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Creative PEGworks
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. NOF
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Quanta BioDesign Celares Biomatrik
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Iris Biotech Laysan Bio
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. ...
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
